Search Results - "Wils, P."

Cataclysmic variables from the Catalina Real-time Transient Survey by Drake, A. J., Gänsicke, B. T., Djorgovski, S. G., Wils, P., Mahabal, A. A., Graham, M. J., Yang, T.-C., Williams, R., Catelan, M., Prieto, J. L., Donalek, C., Larson, S., Christensen, E.

“…We present 855 cataclysmic variable candidates detected by the Catalina Real-time Transient Survey (CRTS) of which at least 137 have been spectroscopically…”
Get full text

Long‐term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience by Wils, P., Bouhnik, Y., Michetti, P., Flourie, B., Brixi, H., Bourrier, A., Allez, M., Duclos, B., Serrero, M., Buisson, A., Amiot, A., Fumery, M., Roblin, X., Peyrin‐Biroulet, L., Filippi, J., Bouguen, G., Abitbol, V., Coffin, B., Simon, M., Laharie, D., Pariente, B.

“…Summary Background Long‐term outcome of ustekinumab in Crohn's disease (CD) has not been evaluated. Aim To evaluate the long‐term efficacy and safety of…”
Get full text

Long‐term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel disease treated with intensified doses: The REMSWITCH‐LT study by Buisson, A., Nachury, M., Bazoge, M., Yzet, C., Wils, P., Dodel, M., Coban, D., Pereira, B., Fumery, M.

“…Summary Background The long‐term risk of relapse after switching from intravenous (IV) to subcutaneous (SC) infliximab remains unknown in inflammatory bowel…”
Get full text

Olmesartan‐associated enteropathy: results of a national survey by Marthey, L., Cadiot, G., Seksik, P., Pouderoux, P., Lacroute, J., Skinazi, F., Mesnard, B., Chayvialle, J. A., Savoye, G., Druez, A., Parlier, D., Abitbol, V., Gompel, M., Eoche, M., Poncin, E., Bobichon, R., Colardelle, P., Wils, P., Salloum, H., Peschard, S., Zerbib, F., Méresse, B., Cerf‐Bensussan, N., Malamut, G., Carbonnel, F.

“…Summary Background Recently, a new enteropathy has been described: olmesartan‐associated enteropathy. However, the association has been questioned: a phase 3…”
Get full text

P733 Long-term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel diseases treated with intensified doses: the REMSWITCH-LT study by Buisson, A, Nachury, M, Bazoge, M, Yzet, C, Wils, P, Dodel, M, Coban, D, Pereira, B, Fumery, M

“…Abstract Background We recently demonstrated that switching from intravenous to subcutaneous infliximab is safe and well-accepted at short-term in IBD patients…”
Get full text

Infliximab is an effective option in patients with ulcerative colitis previously exposed to full subcutaneous anti-TNF agent: Results from a real-world multicenter study by Hupé, M., Streichenberger, A., Wils, P., Arab, N., Serrero, M., Amiot, A., Bozon, A., Vuitton, L., Fumery, M., Altwegg, R., Nachury, M., Hébuterne, X., Yzet, C., Coban, D., Dodel, M., Bazoge, M., Pereira, B., Buisson, A.

“…Data on infliximab efficacy in bio-exposed patients with ulcerative colitis (UC) are limited. To evaluate infliximab effectiveness and its predictors in UC…”
Get full text

Risk of anti-TNF therapy on pregnancy, breastfeeding, live vaccines and related information in patients with inflammatory bowel disease: Real-world data from a nationwide study by Bendaoud, S., Nahon, S., Beaugerie, L., Gornet, J.M., Wils, P., Amiot, A., Peyrin-Biroulet, L., Abitbol, V., Hébuterne, X., Altwegg, R., Rosa, I., Amil, M., Heluwaert, F., Plastaras, L., Stefanescu, C., Quentin, V., Antoni, M., Bideau, K., Boualit, M., Cuillerier, E., Locher, C., Skinazi, F., Boureille, A., Buisson, A., Simon, M.

“…Anti-TNF are usually maintained during pregnancy in patients with inflammatory bowel disease (IBD) but safety is still a concern for them. To provide data on…”
Get full text

P1151 Incidence and risk factors of thromboembolic events in Pediatric-Onset Inflammatory Bowel Disease: a population-based study by Richard, N, Leroyer, A, Ley, D, Dupont, C, Bertrand, V, Wils, P, Gower-Rousseau, C, Turck, D, Guillon, N, Sarter, H, Savoye, G, Fumery, M

“…Abstract Background Patients with inflammatory bowel disease (IBD) are known to be more susceptible to thromboembolic events. However, limited data on the…”
Get full text

P1122 Comorbidities Associated with Pediatric Onset Inflammatory Bowel Diseases: A Population-Based Study by Richard, N, Leroyer, A, Sarter, H, Dupont, C, Turck, D, Bertrand, V, Wils, P, Gower-Rousseau, C, Savoye, G, Guillon, N, Ley, D, Fumery, M

“…Abstract Background Inflammatory bowel disease (IBD) can be associated with various disorders, including dermatological, rheumatological, or psychiatric…”
Get full text

P1125 Incidence and Neoplastic Risk Associated with Colonic Stricture in Pediatric-Onset Crohn's Disease: A Population-based Study by Richard, N, Leroyer, A, Dupont, C, Turck, D, Bertrand, V, Wils, P, Gower-Rousseau, C, Guillon, N, Savoye, G, Ley, D, Sarter, H, Fumery, M

“…Abstract Background The identification of colonic stricture in patients with Crohn's disease (CD) often leads to surgery due to concerns about associated…”
Get full text

P1071 Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAID by Caron, B, Seksik, P, Buisson, A, Wils, P, Savoye, G, Stefanescu, C, Laharie, D, Guillo, L, Abitbol, V, Bonnet, J, Altwegg, R, Vuitton, L, Moussata, D, Bourreille, A, Biron, A, Gilletta, C, Fumery, M, Nahon, S, Nancey, S, Camara, H, Peyrin-Biroulet, L

“…Abstract Background Several adalimumab preparations are now available on the market for patients with inflammatory bowel disease. Comparative satisfaction and…”
Get full text

P679 Anti-TNF de-escalation following a treat-to-target strategy with golimumab therapy intensification to reach continuous clinical response in ulcerative colitis: the In-Target GETAID trial by Vuitton, L, Poullenot, F, Bouhnik, Y, Wils, P, Buisson, A, Viennot, S, Bouguen, G, Hébuterne, X, Gilletta, C, Nancey, S, Bourreille, A, Amil, M, Altwegg, R, Goutorbe, F, Caillo, L, Plastaras, L, Brixi, H, Simon, M, Serrero, M, Fumery, M, Rahier, J F, Vicaut, E, Peyrin-Biroulet, L

“…Abstract Background Achieving deep and continuous remission with tight control could allow de-escalation in patients with UC. The in-TARGET study was a…”
Get full text

Efficacy and safety of golimumab in Crohn's disease: a French national retrospective study by Martineau, C., Flourié, B., Wils, P., Vaysse, T., Altwegg, R., Buisson, A., Amiot, A., Pineton de Chambrun, G., Abitbol, V., Fumery, M., Hébuterne, X., Viennot, S., Laharie, D., Beaugerie, L., Nancey, S., Sokol, H., Abitbol, Vered, Altwegg, Romain, Amiot, Aurélien, Beaugerie, Laurent, Boschetti, Gilles, Bourrier, Anne, Buisson, Anthony, Carbonnel, Frank, Condat, Joris, Cosnes, Jacques, Flourié, Bernard, Fumery, Mathurin, Hébuterne, Xavier, Kirchgesner, Julien, Laharie, David, Landman, Cécilia, Loreau, Julien, Marteau, Philippe, Martineau, Chloé, Mille, Fréderic, Nancey, Stéphane, Nion‐Larmurier, Isabelle, Pineton de Chambrun, Guillaume, Nachury, Maria, Pariente, Benjamin, Seksik, Philippe, Sokol, Harry, Vaysse, Thibaut, Viennot, Stéphanie, Wils, Pauline

“…Summary Background Anti‐tumour necrosis factor (TNF) agents have improved the care of Crohn's disease (CD). After the first anti‐TNF discontinuation, it is…”
Get full text

Folate-targeted, cationic liposome-mediated gene transfer into disseminated peritoneal tumors by REDDY, J. A, ABBURI, C, HOFLAND, H, HOWARD, S. J, VLAHOV, I, WILS, P, LEAMON, C. P

“…A folate-targeted, cationic lipid based transfection complex was developed and found to specifically transfect folate receptor-expressing cells and tumors…”
Get full text

V532 Oph Is a New R Coronae Borealis Star by Clayton, Geoffrey C., Kilkenny, D., Wils, P., Welch, D. L.

“…V532 Oph has been found to be a member of the rare, hydrogen-deficient R Coronae Borealis (RCB) stars from new photometric and spectroscopic data reported in…”
Get full text

V371 Per – A thick-disc, short-period F/1O Cepheid by Wils, P., Henden, A. A., Kleidis, S., Schmidt, E. G., Welch, D. L.

“…V371 Per was found to be a double-mode Cepheid with a fundamental mode period of 1.738 days, the shortest among Galactic beat Cepheids, and an unusually high…”
Get full text

The European Commission’s Cartel Settlement Procedure: An Assessment after 15 Years by Wils, Wouter P J

Get full text

A new DNA vehicle for nonviral gene delivery: supercoiled minicircle by Darquet, A M, Cameron, B, Wils, P, Scherman, D, Crouzet, J

“…Plasmids currently used for nonviral gene transfer have the disadvantage of carrying a bacterial origin of replication and an antibiotic resistance gene. There…”
Get full text

Synthetic DNA-compacting peptides derived from human sequence enhance cationic lipid-mediated gene transfer in vitro and in vivo by SCHWARTZ, B, IVANOV, M.-A, PITARD, B, ESCRIOU, V, RANGARA, R, BYK, G, WILS, P, CROUZET, J, SCHERMAN, D

“…Cationic lipids can deliver genes efficiently in vitro, but are generally inhibited by the presence of serum, and their efficiency in vivo is much lower than…”
Get full text

Efficient purification of plasmid DNA for gene transfer using triple-helix affinity chromatography by WILS, P, ESCRIOU, V, WARNERY, A, LACROIX, F, LAGNEAUX, D, OLLIVIER, M, CROUZET, J, MAYAUX, J.-F, SCHERMAN, D

“…Plasmid DNA used for nonviral therapeutic gene transfer or nucleic acid vaccination has to be highly purified devoid of contaminating components such as…”
Get full text